Natixis’s BioTelemetry, Inc. BEAT Stock Holding History

Natixis’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-68,860	Closed	-$4.96M	–	1227
2020 Q4	$4.96M	Buy	+68,860	New	+$3.6M	0.02%	512
2020 Q3	–	Sell	-162,159	Closed	-$7.33M	–	924
2020 Q2	$7.33M	Sell	162,159 -11,747	-7%	-$526K	0.06%	230
2020 Q1	$6.7M	Sell	173,906 -360	-0.2%	-$16.6K	0.05%	241
2019 Q4	$8.09M	Sell	174,266 -5,234	-3%	-$227K	0.05%	320
2019 Q3	$7.31M	Buy	+179,500	New	+$7.75M	0.05%	298
2019 Q2	–	Sell	-224,513	Closed	-$13.9M	–	966
2019 Q1	$13.9M	Buy	+224,513	New	+$15.4M	0.09%	221
2018 Q3	–	Sell	-319,024	Closed	-$14.4M	–	1050
2018 Q2	$14.4M	Buy	319,024 +4,224	+1%	+$168K	0.08%	228
2018 Q1	$9.78M	Buy	314,800 +114,870	+57%	+$3.78M	0.06%	256
2017 Q4	$5.98M	Buy	199,930 +81,879	+69%	+$2.37M	0.05%	282
2017 Q3	$3.9M	Buy	+118,051	New	+$4.09M	0.04%	310
2017 Q2	–	Sell	-25,189	Closed	-$729K	–	1081
2017 Q1	$729K	Buy	+25,189	New	+$624K	0.01%	451

Other funds holding BEAT

LCM

Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

Natixis's BEAT Position: Q1 2021 in Review

Natixis sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 68,860 shares — an estimated $4.96M sold.

Natixis first reported a position in BEAT in Q1 2017 and held it in 11 quarters. The position peaked at $14.4M in Q2 2018. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

Natixis reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
Natixis sold 68,860 BioTelemetry, Inc. shares in Q1 2021, an estimated $4.96M.
Natixis first reported a position in BioTelemetry, Inc. in Q1 2017 and held it in 11 quarters.
Natixis's BioTelemetry, Inc. position peaked at $14.4M in Q2 2018.
1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Natixis's 13F filing for Q1 2021, filed 14 May 2021.